MorphoSys AG
MorphoSys AG (MOR) Stock Competitors & Peer Comparison
See (MOR) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MOR | $18.96 | +2.43% | 2.9B | -12.64 | -$1.50 | N/A |
| VRTX | $423.24 | -1.60% | 107.7B | 27.63 | $15.32 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $686.36 | -6.21% | 71.3B | 16.54 | $41.49 | +0.53% |
| ARGX | $776.02 | +0.13% | 48B | 39.57 | $19.61 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $301.19 | -0.30% | 40.2B | 129.28 | $2.33 | N/A |
| RVMD | $140.55 | -2.96% | 29.4B | -23.64 | -$5.95 | N/A |
| INSM | $135.03 | +0.07% | 29.1B | -21.03 | -$6.42 | N/A |
| BNTX | $101.57 | -0.48% | 25.5B | -18.47 | -$5.50 | N/A |
Stock Comparison
MOR vs VRTX Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, VRTX has a market cap of 107.7B. Regarding current trading prices, MOR is priced at $18.96, while VRTX trades at $423.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas VRTX's P/E ratio is 27.63. In terms of profitability, MOR's ROE is -1.84%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, MOR is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check VRTX's competition here
MOR vs VRNA Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, MOR is priced at $18.96, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas VRNA's P/E ratio is -102.80. In terms of profitability, MOR's ROE is -1.84%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, MOR is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check VRNA's competition here
MOR vs REGN Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, REGN has a market cap of 71.3B. Regarding current trading prices, MOR is priced at $18.96, while REGN trades at $686.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas REGN's P/E ratio is 16.54. In terms of profitability, MOR's ROE is -1.84%, compared to REGN's ROE of +0.14%. Regarding short-term risk, MOR is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for MOR.Check REGN's competition here
MOR vs ARGX Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, ARGX has a market cap of 48B. Regarding current trading prices, MOR is priced at $18.96, while ARGX trades at $776.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas ARGX's P/E ratio is 39.57. In terms of profitability, MOR's ROE is -1.84%, compared to ARGX's ROE of +0.34%. Regarding short-term risk, MOR is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check ARGX's competition here
MOR vs SGEN Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, MOR is priced at $18.96, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas SGEN's P/E ratio is -57.19. In terms of profitability, MOR's ROE is -1.84%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, MOR is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check SGEN's competition here
MOR vs ALNY Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, ALNY has a market cap of 40.2B. Regarding current trading prices, MOR is priced at $18.96, while ALNY trades at $301.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas ALNY's P/E ratio is 129.28. In terms of profitability, MOR's ROE is -1.84%, compared to ALNY's ROE of +0.90%. Regarding short-term risk, MOR is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check ALNY's competition here
MOR vs RVMD Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, RVMD has a market cap of 29.4B. Regarding current trading prices, MOR is priced at $18.96, while RVMD trades at $140.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas RVMD's P/E ratio is -23.64. In terms of profitability, MOR's ROE is -1.84%, compared to RVMD's ROE of -0.63%. Regarding short-term risk, MOR is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check RVMD's competition here
MOR vs INSM Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, INSM has a market cap of 29.1B. Regarding current trading prices, MOR is priced at $18.96, while INSM trades at $135.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas INSM's P/E ratio is -21.03. In terms of profitability, MOR's ROE is -1.84%, compared to INSM's ROE of -1.68%. Regarding short-term risk, MOR is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check INSM's competition here
MOR vs BNTX Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, BNTX has a market cap of 25.5B. Regarding current trading prices, MOR is priced at $18.96, while BNTX trades at $101.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas BNTX's P/E ratio is -18.47. In terms of profitability, MOR's ROE is -1.84%, compared to BNTX's ROE of -0.06%. Regarding short-term risk, MOR is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check BNTX's competition here
MOR vs UTHR Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, UTHR has a market cap of 25B. Regarding current trading prices, MOR is priced at $18.96, while UTHR trades at $571.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas UTHR's P/E ratio is 20.51. In terms of profitability, MOR's ROE is -1.84%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, MOR is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check UTHR's competition here
MOR vs RPRX Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, RPRX has a market cap of 21.2B. Regarding current trading prices, MOR is priced at $18.96, while RPRX trades at $49.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas RPRX's P/E ratio is 27.80. In terms of profitability, MOR's ROE is -1.84%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, MOR is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check RPRX's competition here
MOR vs BGNE Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, MOR is priced at $18.96, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas BGNE's P/E ratio is -22.55. In terms of profitability, MOR's ROE is -1.84%, compared to BGNE's ROE of +0.07%. Regarding short-term risk, MOR is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check BGNE's competition here
MOR vs INCY Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, INCY has a market cap of 19.7B. Regarding current trading prices, MOR is priced at $18.96, while INCY trades at $99.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas INCY's P/E ratio is 15.46. In terms of profitability, MOR's ROE is -1.84%, compared to INCY's ROE of +0.29%. Regarding short-term risk, MOR is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for MOR.Check INCY's competition here
MOR vs ROIV Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, ROIV has a market cap of 19.7B. Regarding current trading prices, MOR is priced at $18.96, while ROIV trades at $27.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas ROIV's P/E ratio is -23.52. In terms of profitability, MOR's ROE is -1.84%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, MOR is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check ROIV's competition here
MOR vs DNA-WT Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, MOR is priced at $18.96, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, MOR's ROE is -1.84%, compared to DNA-WT's ROE of -0.54%. Regarding short-term risk, MOR is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for MOR.Check DNA-WT's competition here
MOR vs MRNA Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, MRNA has a market cap of 18.1B. Regarding current trading prices, MOR is priced at $18.96, while MRNA trades at $45.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas MRNA's P/E ratio is -6.30. In terms of profitability, MOR's ROE is -1.84%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, MOR is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for MOR.Check MRNA's competition here
MOR vs SMMT Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, SMMT has a market cap of 16.2B. Regarding current trading prices, MOR is priced at $18.96, while SMMT trades at $20.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas SMMT's P/E ratio is -14.47. In terms of profitability, MOR's ROE is -1.84%, compared to SMMT's ROE of -2.97%. Regarding short-term risk, MOR is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for MOR.Check SMMT's competition here
MOR vs GMAB Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, GMAB has a market cap of 16.1B. Regarding current trading prices, MOR is priced at $18.96, while GMAB trades at $26.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas GMAB's P/E ratio is 16.95. In terms of profitability, MOR's ROE is -1.84%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, MOR is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check GMAB's competition here
MOR vs BBIO Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, BBIO has a market cap of 13.8B. Regarding current trading prices, MOR is priced at $18.96, while BBIO trades at $70.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas BBIO's P/E ratio is -18.77. In terms of profitability, MOR's ROE is -1.84%, compared to BBIO's ROE of +0.39%. Regarding short-term risk, MOR is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for MOR.Check BBIO's competition here
MOR vs ASND Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, ASND has a market cap of 13.5B. Regarding current trading prices, MOR is priced at $18.96, while ASND trades at $220.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas ASND's P/E ratio is -50.06. In terms of profitability, MOR's ROE is -1.84%, compared to ASND's ROE of +1.28%. Regarding short-term risk, MOR is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check ASND's competition here
MOR vs KRTX Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, MOR is priced at $18.96, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas KRTX's P/E ratio is -28.09. In terms of profitability, MOR's ROE is -1.84%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, MOR is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check KRTX's competition here
MOR vs IONS Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, IONS has a market cap of 12.4B. Regarding current trading prices, MOR is priced at $18.96, while IONS trades at $74.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas IONS's P/E ratio is -31.44. In terms of profitability, MOR's ROE is -1.84%, compared to IONS's ROE of -0.59%. Regarding short-term risk, MOR is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for MOR.Check IONS's competition here
MOR vs JAZZ Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, JAZZ has a market cap of 12.3B. Regarding current trading prices, MOR is priced at $18.96, while JAZZ trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas JAZZ's P/E ratio is -34.23. In terms of profitability, MOR's ROE is -1.84%, compared to JAZZ's ROE of -0.09%. Regarding short-term risk, MOR is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check JAZZ's competition here
MOR vs MDGL Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, MDGL has a market cap of 11.9B. Regarding current trading prices, MOR is priced at $18.96, while MDGL trades at $518.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas MDGL's P/E ratio is -40.33. In terms of profitability, MOR's ROE is -1.84%, compared to MDGL's ROE of -0.44%. Regarding short-term risk, MOR is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check MDGL's competition here
MOR vs EXEL Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, EXEL has a market cap of 11.4B. Regarding current trading prices, MOR is priced at $18.96, while EXEL trades at $44.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas EXEL's P/E ratio is 16.08. In terms of profitability, MOR's ROE is -1.84%, compared to EXEL's ROE of +0.37%. Regarding short-term risk, MOR is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check EXEL's competition here
MOR vs RNAM Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, MOR is priced at $18.96, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas RNAM's P/E ratio is -17.39. In terms of profitability, MOR's ROE is -1.84%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, MOR is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check RNAM's competition here
MOR vs BMRN Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, BMRN has a market cap of 10.4B. Regarding current trading prices, MOR is priced at $18.96, while BMRN trades at $54.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas BMRN's P/E ratio is 30.12. In terms of profitability, MOR's ROE is -1.84%, compared to BMRN's ROE of +0.06%. Regarding short-term risk, MOR is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check BMRN's competition here
MOR vs ARWR Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, ARWR has a market cap of 9.9B. Regarding current trading prices, MOR is priced at $18.96, while ARWR trades at $70.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas ARWR's P/E ratio is 44.08. In terms of profitability, MOR's ROE is -1.84%, compared to ARWR's ROE of +0.36%. Regarding short-term risk, MOR is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check ARWR's competition here
MOR vs RXDX Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, MOR is priced at $18.96, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas RXDX's P/E ratio is -56.47. In terms of profitability, MOR's ROE is -1.84%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, MOR is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check RXDX's competition here
MOR vs AXSM Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, AXSM has a market cap of 9.4B. Regarding current trading prices, MOR is priced at $18.96, while AXSM trades at $183.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas AXSM's P/E ratio is -49.98. In terms of profitability, MOR's ROE is -1.84%, compared to AXSM's ROE of -2.54%. Regarding short-term risk, MOR is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check AXSM's competition here
MOR vs IMGN Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, MOR is priced at $18.96, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas IMGN's P/E ratio is -111.55. In terms of profitability, MOR's ROE is -1.84%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, MOR is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check IMGN's competition here
MOR vs BPMC Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, MOR is priced at $18.96, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas BPMC's P/E ratio is -51.58. In terms of profitability, MOR's ROE is -1.84%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, MOR is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check BPMC's competition here
MOR vs PCVX Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, PCVX has a market cap of 8.2B. Regarding current trading prices, MOR is priced at $18.96, while PCVX trades at $57.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas PCVX's P/E ratio is -10.18. In terms of profitability, MOR's ROE is -1.84%, compared to PCVX's ROE of -0.26%. Regarding short-term risk, MOR is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check PCVX's competition here
MOR vs CERE Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, MOR is priced at $18.96, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas CERE's P/E ratio is -16.47. In terms of profitability, MOR's ROE is -1.84%, compared to CERE's ROE of -0.72%. Regarding short-term risk, MOR is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check CERE's competition here
MOR vs TECH Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, TECH has a market cap of 8.1B. Regarding current trading prices, MOR is priced at $18.96, while TECH trades at $51.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas TECH's P/E ratio is 98.06. In terms of profitability, MOR's ROE is -1.84%, compared to TECH's ROE of +0.04%. Regarding short-term risk, MOR is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for MOR.Check TECH's competition here
MOR vs KRYS Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, KRYS has a market cap of 7.7B. Regarding current trading prices, MOR is priced at $18.96, while KRYS trades at $259.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas KRYS's P/E ratio is 37.95. In terms of profitability, MOR's ROE is -1.84%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, MOR is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for MOR.Check KRYS's competition here
MOR vs HALO Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, HALO has a market cap of 7.5B. Regarding current trading prices, MOR is priced at $18.96, while HALO trades at $63.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas HALO's P/E ratio is 24.63. In terms of profitability, MOR's ROE is -1.84%, compared to HALO's ROE of +0.93%. Regarding short-term risk, MOR is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check HALO's competition here
MOR vs MTSR Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, MOR is priced at $18.96, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas MTSR's P/E ratio is -23.58. In terms of profitability, MOR's ROE is -1.84%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, MOR is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check MTSR's competition here
MOR vs CYTK Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, CYTK has a market cap of 7.3B. Regarding current trading prices, MOR is priced at $18.96, while CYTK trades at $59.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas CYTK's P/E ratio is -9.11. In terms of profitability, MOR's ROE is -1.84%, compared to CYTK's ROE of +1.73%. Regarding short-term risk, MOR is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check CYTK's competition here
MOR vs NUVL Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, NUVL has a market cap of 7.3B. Regarding current trading prices, MOR is priced at $18.96, while NUVL trades at $99.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas NUVL's P/E ratio is -16.94. In terms of profitability, MOR's ROE is -1.84%, compared to NUVL's ROE of -0.42%. Regarding short-term risk, MOR is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check NUVL's competition here
MOR vs IBRX Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, IBRX has a market cap of 7.2B. Regarding current trading prices, MOR is priced at $18.96, while IBRX trades at $6.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas IBRX's P/E ratio is -18.32. In terms of profitability, MOR's ROE is -1.84%, compared to IBRX's ROE of +0.64%. Regarding short-term risk, MOR is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check IBRX's competition here
MOR vs ABVX Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, ABVX has a market cap of 7B. Regarding current trading prices, MOR is priced at $18.96, while ABVX trades at $106.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas ABVX's P/E ratio is -18.77. In terms of profitability, MOR's ROE is -1.84%, compared to ABVX's ROE of -1.59%. Regarding short-term risk, MOR is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check ABVX's competition here
MOR vs PRAX Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, PRAX has a market cap of 6.8B. Regarding current trading prices, MOR is priced at $18.96, while PRAX trades at $323.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas PRAX's P/E ratio is -23.98. In terms of profitability, MOR's ROE is -1.84%, compared to PRAX's ROE of -0.59%. Regarding short-term risk, MOR is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check PRAX's competition here
MOR vs MRUS Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, MOR is priced at $18.96, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas MRUS's P/E ratio is -17.05. In terms of profitability, MOR's ROE is -1.84%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, MOR is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check MRUS's competition here
MOR vs ACLX Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, MOR is priced at $18.96, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas ACLX's P/E ratio is -28.27. In terms of profitability, MOR's ROE is -1.84%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, MOR is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check ACLX's competition here
MOR vs KYMR Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, KYMR has a market cap of 6.7B. Regarding current trading prices, MOR is priced at $18.96, while KYMR trades at $81.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas KYMR's P/E ratio is -22.09. In terms of profitability, MOR's ROE is -1.84%, compared to KYMR's ROE of -0.29%. Regarding short-term risk, MOR is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check KYMR's competition here
MOR vs RETA Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, MOR is priced at $18.96, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas RETA's P/E ratio is -66.29. In terms of profitability, MOR's ROE is -1.84%, compared to RETA's ROE of +0.47%. Regarding short-term risk, MOR is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check RETA's competition here
MOR vs PTGX Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, PTGX has a market cap of 6.3B. Regarding current trading prices, MOR is priced at $18.96, while PTGX trades at $98.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas PTGX's P/E ratio is -48.08. In terms of profitability, MOR's ROE is -1.84%, compared to PTGX's ROE of -0.20%. Regarding short-term risk, MOR is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check PTGX's competition here
MOR vs BLTE Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, BLTE has a market cap of 6.2B. Regarding current trading prices, MOR is priced at $18.96, while BLTE trades at $154.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas BLTE's P/E ratio is -66.59. In terms of profitability, MOR's ROE is -1.84%, compared to BLTE's ROE of -0.23%. Regarding short-term risk, MOR is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check BLTE's competition here
MOR vs CNTA Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, CNTA has a market cap of 5.9B. Regarding current trading prices, MOR is priced at $18.96, while CNTA trades at $39.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas CNTA's P/E ratio is -27.02. In terms of profitability, MOR's ROE is -1.84%, compared to CNTA's ROE of -0.51%. Regarding short-term risk, MOR is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check CNTA's competition here
MOR vs COGT Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, COGT has a market cap of 5.8B. Regarding current trading prices, MOR is priced at $18.96, while COGT trades at $35.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas COGT's P/E ratio is -16.61. In terms of profitability, MOR's ROE is -1.84%, compared to COGT's ROE of -1.00%. Regarding short-term risk, MOR is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check COGT's competition here
MOR vs CELC Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, CELC has a market cap of 5.8B. Regarding current trading prices, MOR is priced at $18.96, while CELC trades at $119.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas CELC's P/E ratio is -31.40. In terms of profitability, MOR's ROE is -1.84%, compared to CELC's ROE of -2.03%. Regarding short-term risk, MOR is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for MOR.Check CELC's competition here
MOR vs ALKS Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, ALKS has a market cap of 5.6B. Regarding current trading prices, MOR is priced at $18.96, while ALKS trades at $33.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas ALKS's P/E ratio is 23.57. In terms of profitability, MOR's ROE is -1.84%, compared to ALKS's ROE of +0.14%. Regarding short-term risk, MOR is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check ALKS's competition here
MOR vs CDTX Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, MOR is priced at $18.96, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas CDTX's P/E ratio is -19.77. In terms of profitability, MOR's ROE is -1.84%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, MOR is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check CDTX's competition here
MOR vs RYTM Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, RYTM has a market cap of 5.6B. Regarding current trading prices, MOR is priced at $18.96, while RYTM trades at $82.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas RYTM's P/E ratio is -26.41. In terms of profitability, MOR's ROE is -1.84%, compared to RYTM's ROE of -1.79%. Regarding short-term risk, MOR is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check RYTM's competition here
MOR vs ABCM Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, MOR is priced at $18.96, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, MOR's ROE is -1.84%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, MOR is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check ABCM's competition here
MOR vs ISEE Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, MOR is priced at $18.96, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas ISEE's P/E ratio is -22.44. In terms of profitability, MOR's ROE is -1.84%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, MOR is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check ISEE's competition here
MOR vs IMVT Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, IMVT has a market cap of 5.5B. Regarding current trading prices, MOR is priced at $18.96, while IMVT trades at $26.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas IMVT's P/E ratio is -10.09. In terms of profitability, MOR's ROE is -1.84%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, MOR is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for MOR.Check IMVT's competition here
MOR vs CGON Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, CGON has a market cap of 5.5B. Regarding current trading prices, MOR is priced at $18.96, while CGON trades at $64.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas CGON's P/E ratio is -31.13. In terms of profitability, MOR's ROE is -1.84%, compared to CGON's ROE of -0.23%. Regarding short-term risk, MOR is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check CGON's competition here
MOR vs TGTX Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, TGTX has a market cap of 5.4B. Regarding current trading prices, MOR is priced at $18.96, while TGTX trades at $33.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas TGTX's P/E ratio is 12.12. In terms of profitability, MOR's ROE is -1.84%, compared to TGTX's ROE of +1.01%. Regarding short-term risk, MOR is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check TGTX's competition here
MOR vs PTCT Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, PTCT has a market cap of 5.3B. Regarding current trading prices, MOR is priced at $18.96, while PTCT trades at $64.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas PTCT's P/E ratio is 7.52. In terms of profitability, MOR's ROE is -1.84%, compared to PTCT's ROE of -3.62%. Regarding short-term risk, MOR is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for MOR.Check PTCT's competition here
MOR vs SRRK Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, SRRK has a market cap of 5.3B. Regarding current trading prices, MOR is priced at $18.96, while SRRK trades at $46.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas SRRK's P/E ratio is -14.07. In terms of profitability, MOR's ROE is -1.84%, compared to SRRK's ROE of -1.46%. Regarding short-term risk, MOR is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for MOR.Check SRRK's competition here
MOR vs APLS Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, APLS has a market cap of 5.2B. Regarding current trading prices, MOR is priced at $18.96, while APLS trades at $40.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas APLS's P/E ratio is 227.59. In terms of profitability, MOR's ROE is -1.84%, compared to APLS's ROE of +0.08%. Regarding short-term risk, MOR is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check APLS's competition here
MOR vs FBIOX Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, FBIOX has a market cap of 5.1B. Regarding current trading prices, MOR is priced at $18.96, while FBIOX trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas FBIOX's P/E ratio is N/A. In terms of profitability, MOR's ROE is -1.84%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, MOR is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check FBIOX's competition here
MOR vs CAI Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, CAI has a market cap of 5B. Regarding current trading prices, MOR is priced at $18.96, while CAI trades at $17.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas CAI's P/E ratio is -5.52. In terms of profitability, MOR's ROE is -1.84%, compared to CAI's ROE of +0.25%. Regarding short-term risk, MOR is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for MOR.Check CAI's competition here
MOR vs CORT Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, CORT has a market cap of 5B. Regarding current trading prices, MOR is priced at $18.96, while CORT trades at $46.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas CORT's P/E ratio is 56.82. In terms of profitability, MOR's ROE is -1.84%, compared to CORT's ROE of +0.15%. Regarding short-term risk, MOR is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check CORT's competition here
MOR vs CRSP Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, CRSP has a market cap of 4.9B. Regarding current trading prices, MOR is priced at $18.96, while CRSP trades at $50.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas CRSP's P/E ratio is -7.84. In terms of profitability, MOR's ROE is -1.84%, compared to CRSP's ROE of -0.32%. Regarding short-term risk, MOR is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check CRSP's competition here
MOR vs TERN Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, MOR is priced at $18.96, while TERN trades at $52.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas TERN's P/E ratio is -51.38. In terms of profitability, MOR's ROE is -1.84%, compared to TERN's ROE of -0.20%. Regarding short-term risk, MOR is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check TERN's competition here
MOR vs MIRM Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, MIRM has a market cap of 4.7B. Regarding current trading prices, MOR is priced at $18.96, while MIRM trades at $94.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas MIRM's P/E ratio is -200.43. In terms of profitability, MOR's ROE is -1.84%, compared to MIRM's ROE of -0.09%. Regarding short-term risk, MOR is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check MIRM's competition here
MOR vs APGE Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, APGE has a market cap of 4.6B. Regarding current trading prices, MOR is priced at $18.96, while APGE trades at $82.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas APGE's P/E ratio is -19.44. In terms of profitability, MOR's ROE is -1.84%, compared to APGE's ROE of -0.37%. Regarding short-term risk, MOR is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for MOR.Check APGE's competition here
MOR vs FOLD Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, MOR is priced at $18.96, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas FOLD's P/E ratio is -161.00. In terms of profitability, MOR's ROE is -1.84%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, MOR is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check FOLD's competition here
MOR vs AKRO Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, MOR is priced at $18.96, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas AKRO's P/E ratio is -14.57. In terms of profitability, MOR's ROE is -1.84%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, MOR is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check AKRO's competition here
MOR vs LGND Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, LGND has a market cap of 4.5B. Regarding current trading prices, MOR is priced at $18.96, while LGND trades at $224.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas LGND's P/E ratio is 36.68. In terms of profitability, MOR's ROE is -1.84%, compared to LGND's ROE of +0.14%. Regarding short-term risk, MOR is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check LGND's competition here
MOR vs ALPN Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, MOR is priced at $18.96, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas ALPN's P/E ratio is -101.52. In terms of profitability, MOR's ROE is -1.84%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, MOR is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check ALPN's competition here
MOR vs XENE Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, XENE has a market cap of 4.4B. Regarding current trading prices, MOR is priced at $18.96, while XENE trades at $55.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas XENE's P/E ratio is -12.79. In terms of profitability, MOR's ROE is -1.84%, compared to XENE's ROE of -0.56%. Regarding short-term risk, MOR is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for MOR.Check XENE's competition here
MOR vs SYRE Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, SYRE has a market cap of 4.3B. Regarding current trading prices, MOR is priced at $18.96, while SYRE trades at $71.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas SYRE's P/E ratio is -36.31. In terms of profitability, MOR's ROE is -1.84%, compared to SYRE's ROE of -0.29%. Regarding short-term risk, MOR is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for MOR.Check SYRE's competition here
MOR vs OPT Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, MOR is priced at $18.96, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas OPT's P/E ratio is -1.52. In terms of profitability, MOR's ROE is -1.84%, compared to OPT's ROE of +0.88%. Regarding short-term risk, MOR is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check OPT's competition here
MOR vs LEGN Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, LEGN has a market cap of 4.2B. Regarding current trading prices, MOR is priced at $18.96, while LEGN trades at $22.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas LEGN's P/E ratio is -14.15. In terms of profitability, MOR's ROE is -1.84%, compared to LEGN's ROE of -0.29%. Regarding short-term risk, MOR is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for MOR.Check LEGN's competition here
MOR vs MRTX Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, MOR is priced at $18.96, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas MRTX's P/E ratio is -4.82. In terms of profitability, MOR's ROE is -1.84%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, MOR is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check MRTX's competition here
MOR vs CRNX Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, CRNX has a market cap of 4B. Regarding current trading prices, MOR is priced at $18.96, while CRNX trades at $38.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas CRNX's P/E ratio is -7.77. In terms of profitability, MOR's ROE is -1.84%, compared to CRNX's ROE of -0.41%. Regarding short-term risk, MOR is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check CRNX's competition here
MOR vs MANE Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, MANE has a market cap of 4B. Regarding current trading prices, MOR is priced at $18.96, while MANE trades at $106.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas MANE's P/E ratio is -45.04. In terms of profitability, MOR's ROE is -1.84%, compared to MANE's ROE of -0.76%. Regarding short-term risk, MOR is less volatile compared to MANE. This indicates potentially lower risk in terms of short-term price fluctuations for MOR.Check MANE's competition here
MOR vs KNSA Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, KNSA has a market cap of 3.9B. Regarding current trading prices, MOR is priced at $18.96, while KNSA trades at $52.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas KNSA's P/E ratio is 58.23. In terms of profitability, MOR's ROE is -1.84%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, MOR is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check KNSA's competition here
MOR vs ACAD Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, ACAD has a market cap of 3.8B. Regarding current trading prices, MOR is priced at $18.96, while ACAD trades at $22.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas ACAD's P/E ratio is 9.65. In terms of profitability, MOR's ROE is -1.84%, compared to ACAD's ROE of +0.42%. Regarding short-term risk, MOR is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check ACAD's competition here
MOR vs RYZB Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, MOR is priced at $18.96, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas RYZB's P/E ratio is -57.86. In terms of profitability, MOR's ROE is -1.84%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, MOR is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check RYZB's competition here
MOR vs CBAY Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, MOR is priced at $18.96, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas CBAY's P/E ratio is -32.81. In terms of profitability, MOR's ROE is -1.84%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, MOR is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check CBAY's competition here
MOR vs TVTX Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, TVTX has a market cap of 3.7B. Regarding current trading prices, MOR is priced at $18.96, while TVTX trades at $40.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas TVTX's P/E ratio is -70.35. In terms of profitability, MOR's ROE is -1.84%, compared to TVTX's ROE of -0.79%. Regarding short-term risk, MOR is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check TVTX's competition here
MOR vs VKTX Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, VKTX has a market cap of 3.6B. Regarding current trading prices, MOR is priced at $18.96, while VKTX trades at $31.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas VKTX's P/E ratio is -9.82. In terms of profitability, MOR's ROE is -1.84%, compared to VKTX's ROE of -0.48%. Regarding short-term risk, MOR is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check VKTX's competition here
MOR vs SWTX Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, MOR is priced at $18.96, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas SWTX's P/E ratio is -13.78. In terms of profitability, MOR's ROE is -1.84%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, MOR is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check SWTX's competition here
MOR vs TLX Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, TLX has a market cap of 3.5B. Regarding current trading prices, MOR is priced at $18.96, while TLX trades at $10.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas TLX's P/E ratio is -521.50. In terms of profitability, MOR's ROE is -1.84%, compared to TLX's ROE of -0.02%. Regarding short-term risk, MOR is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check TLX's competition here
MOR vs CPRX Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, CPRX has a market cap of 3.5B. Regarding current trading prices, MOR is priced at $18.96, while CPRX trades at $28.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas CPRX's P/E ratio is 16.82. In terms of profitability, MOR's ROE is -1.84%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, MOR is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check CPRX's competition here
MOR vs LQDA Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, LQDA has a market cap of 3.4B. Regarding current trading prices, MOR is priced at $18.96, while LQDA trades at $38.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas LQDA's P/E ratio is -47.69. In terms of profitability, MOR's ROE is -1.84%, compared to LQDA's ROE of -2.09%. Regarding short-term risk, MOR is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check LQDA's competition here
MOR vs NAMS Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, NAMS has a market cap of 3.3B. Regarding current trading prices, MOR is priced at $18.96, while NAMS trades at $28.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas NAMS's P/E ratio is -16.53. In terms of profitability, MOR's ROE is -1.84%, compared to NAMS's ROE of -0.27%. Regarding short-term risk, MOR is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check NAMS's competition here
MOR vs EWTX Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, EWTX has a market cap of 3.3B. Regarding current trading prices, MOR is priced at $18.96, while EWTX trades at $30.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas EWTX's P/E ratio is -18.68. In terms of profitability, MOR's ROE is -1.84%, compared to EWTX's ROE of -0.32%. Regarding short-term risk, MOR is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check EWTX's competition here
MOR vs DNTH Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, DNTH has a market cap of 3.2B. Regarding current trading prices, MOR is priced at $18.96, while DNTH trades at $83.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas DNTH's P/E ratio is -19.88. In terms of profitability, MOR's ROE is -1.84%, compared to DNTH's ROE of +0.00%. Regarding short-term risk, MOR is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check DNTH's competition here
MOR vs BEAM Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, BEAM has a market cap of 3B. Regarding current trading prices, MOR is priced at $18.96, while BEAM trades at $29.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas BEAM's P/E ratio is -36.27. In terms of profitability, MOR's ROE is -1.84%, compared to BEAM's ROE of -0.07%. Regarding short-term risk, MOR is less volatile compared to BEAM. This indicates potentially lower risk in terms of short-term price fluctuations for MOR.Check BEAM's competition here
MOR vs DNLI Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, DNLI has a market cap of 3B. Regarding current trading prices, MOR is priced at $18.96, while DNLI trades at $18.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas DNLI's P/E ratio is -6.26. In terms of profitability, MOR's ROE is -1.84%, compared to DNLI's ROE of -0.50%. Regarding short-term risk, MOR is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for MOR.Check DNLI's competition here
MOR vs DYN Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, DYN has a market cap of 2.9B. Regarding current trading prices, MOR is priced at $18.96, while DYN trades at $17.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas DYN's P/E ratio is -5.02. In terms of profitability, MOR's ROE is -1.84%, compared to DYN's ROE of -0.61%. Regarding short-term risk, MOR is more volatile compared to DYN. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check DYN's competition here
MOR vs MORF Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, MOR is priced at $18.96, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas MORF's P/E ratio is -14.88. In terms of profitability, MOR's ROE is -1.84%, compared to MORF's ROE of -0.29%. Regarding short-term risk, MOR is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for MOR.Check MORF's competition here
MOR vs ERAS Comparison May 2026
MOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR stands at 2.9B. In comparison, ERAS has a market cap of 2.8B. Regarding current trading prices, MOR is priced at $18.96, while ERAS trades at $9.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR currently has a P/E ratio of -12.64, whereas ERAS's P/E ratio is -20.70. In terms of profitability, MOR's ROE is -1.84%, compared to ERAS's ROE of -0.34%. Regarding short-term risk, MOR is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for MOR.Check ERAS's competition here